Drug
Oxymorphone
Oxymorphone is a pharmaceutical drug with 5 clinical trials. Historical success rate of 80.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_1
2
40%
Ph early_phase_1
1
20%
Ph not_applicable
2
40%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
2(40.0%)
N/ANon-phased studies
2(40.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 1
Trials by Phase
Early Phase 11 (20.0%)
Phase 12 (40.0%)
N/A2 (40.0%)
Trials by Status
terminated120%
completed480%
Recent Activity
0 active trials
Showing 5 of 5
terminatedearly_phase_1
Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer
NCT03579446
completednot_applicable
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis
NCT02625181
completedphase_1
Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions
NCT01210638
completedphase_1
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions
NCT00857428
completednot_applicable
A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)
NCT00580294
Clinical Trials (5)
Showing 5 of 5 trials
NCT03579446Early Phase 1
Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer
NCT02625181Not Applicable
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis
NCT01210638Phase 1
Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions
NCT00857428Phase 1
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions
NCT00580294Not Applicable
A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5